HIV Infections Clinical Trial
Official title:
Improving Quality of Life for Adults Living With HIV and Chronic Pain
Verified date | April 2024 |
Source | Temple University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Chronic pain is highly comorbid among the 1.2 million persons living with HIV, with recent prevalence estimates ranging from 55-67%. Needed are evidenced-based non-pharmacological interventions to improve chronic pain management and reduce the demand for opioids in the United States. The proposed research will address this need by examining the feasibility and acceptability of Tai Chi as a mind-body intervention for chronic pain management in an HIV population.
Status | Active, not recruiting |
Enrollment | 36 |
Est. completion date | December 15, 2024 |
Est. primary completion date | December 15, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - age 45 and older; - HIV positive status based on clinical records; - chronic pain condition based on clinical records; - English speaking; - physically able to participate in a Tai Chi program Exclusion Criteria: - Inability or unwillingness to provide informed consent - Inability or unwillingness to travel to Temple Dental School; - Inability or unwillingness to engage in 10-week intervention; - Non-English speaking; - Active substance use disorder; - Acutely suicidal or psychotic; - Self-reported participation in another research study related to chronic-pain |
Country | Name | City | State |
---|---|---|---|
United States | Temple University Kornberg School of Dentistry (TUKSoD) | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Temple University | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Feasibility | Ability to recruit and retain participants through intervention and follow-up assessments | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Other | Acceptability | Participant self-reported satisfaction with intervention components | Post-Intervention (Weeks 10-12) | |
Primary | Pain Rating (VAS) | Participants will be asked to rate their pain on a visual analog scale (ranging from 0, no pain, to 100, most extreme pain) | Each intervention group session (10 weeks) | |
Primary | Brief Pain Inventory - Short Form (BPI) | A self-report of pain intensity, impairment in mobility, impairment in activities of daily living, mood, and pain-related anxiety/fear | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Primary | Subjective Peripheral Neuropathy Screen Questionnaire (SPNSQ) | A valid and reliable measure of neuropathic pain symptoms for PLWH | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Primary | Orebro Musculoskeletal Pain Screening Questionnaire (OMSPQ) | Measure used to assess musculoskeletal pain, with questions related pain site, and duration | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Secondary | Quality of Life (WHO-QOL-BREF) | Measure to assess feelings regarding quality of life, health, or other areas of one's life | Baseline (Week 0), Post-Intervention (Weeks 10-12), and 3-month Follow Up (Weeks 22-24) | |
Secondary | Perceived Stress Scale (PSS) | Measure to assess frequency and severity of stressful situations, which may be relevant for people living with HIV and chronic pain as they manage intersecting chronic illnesses | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Secondary | Patient Health Questionnaire (PHQ-8) | The PHQ-9 is a commonly used measure of depression with strong psychometric properties for clinical populations | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Secondary | Pain Catastrophizing Scale (PCS) | 13-item self-report measure designed to assess catastrophic thinking related to pain among adults with or without chronic pain. | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) | |
Secondary | The Meditative Movement Inventory | This is a 17-item questionnaire aiming to capture in descriptions different aspects of meditative movement, such as the meditative state of mind, breathing, flow of movement and affective quality. | Post-Intervention (Weeks 10-12) | |
Secondary | The HIV Medication Adherence Survey | Medication adherence will be assessed using a validated brief 3-item measure for PLWH, which assesses number of days missed, difficulty following instructions, and self-rating of medication adherence in the past 30 days | Baseline (Week 0), Post-Intervention (Weeks 10-12), 3-month Follow Up (Weeks 22-24) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |